Author: admin

  • Anna Turley – 2016 Parliamentary Question to the Department of Health

    Anna Turley – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Anna Turley on 2016-04-19.

    To ask the Secretary of State for Health, what comparative information his Department holds on the rate of pregnancies affected by neural tube defects in the UK and in other EU member states.

    Ben Gummer

    The prevalence of neural tube defects in live births, fetal deaths (over 20 weeks’ gestation) and terminations of pregnancy for fetal anomaly in 2012 in the British Isles Network of Congenital Anomaly Registers, registers (covering 36% of the births in England and Wales) was 12.5 per 10,000 births (source: Congenital anomaly statistics 2012, England and Wales (2014)).

    In European Surveillance of Congenital Anomalies registries (covering 25.8% of the births in the United Kingdom) the prevalence of neural tube defects in 2012 for the UK was 12.53 neural tube defects per 10,000 births. By comparison, other European Union member states ranged from 1.75 per 10,000 births to 17.37 per 10,000 births. Differences in total prevalence rates may reflect a number of factors including genetic and environmental differences.

    Data on prevalence is available at:

    http://www.eurocat-network.eu/AccessPrevalenceData/PrevalenceTables

    “

  • Rob Marris – 2016 Parliamentary Question to the Department of Health

    Rob Marris – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Rob Marris on 2016-04-19.

    To ask the Secretary of State for Health, what discussions his Department has had with NHS England on commissioning of integrated paediatric continence services.

    Jane Ellison

    In November 2015, NHS England published the Commissioning Framework for Continence Services Excellence in Continence Care.

    This covers all ages including children and outlines a pathway including assessment, diagnosis and treatment to recovery where possible. The framework sets out a number of principles for a good design of service including integration across primary, secondary and tertiary services, health, education and social care.

    The framework references the Paediatric Continence Commissioning Guide (2014) which provides a specification for paediatric continence services which again puts integration at its heart.

    A national Excellence in Continence Care Board, chaired by NHS England and with membership of paediatric continence specialists and the Paediatric Forum continues to oversee the implementation of the Excellence in Continence Care framework.

  • Barry Sheerman – 2016 Parliamentary Question to the Department of Health

    Barry Sheerman – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Barry Sheerman on 2016-04-19.

    To ask the Secretary of State for Health, if he will expand the scope of the Learning Disability Mortality Review to include people with autism and a learning disability.

    Alistair Burt

    The National Health Service is taking action to reduce premature death by increasing annual health checks for people with learning disabilities, including for those who also have autism. The NHS is working to reduce variation and improve care for physical health conditions that disproportionately impact on people with learning disabilities who also may have autism, including epilepsy and cancer. NHS England has commissioned the world’s first Learning Disability Mortality Review Programme to support local areas to review deaths of people with learning disabilities and to use the information to improve service provision. This review programme for people with learning disabilities includes those who also have autism.

    Think Autism set out a clear, cross Government programme of action, developed alongside people with autism, their families and carers to improve their lives and reduce premature mortality through better access to healthcare by making adjustments to services. This includes supporting the Royal College of General Practitioners Autism Initiative to improve understanding of autism amongst general practitioners (GPs).

  • Kate Green – 2016 Parliamentary Question to the Department of Health

    Kate Green – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Kate Green on 2016-04-19.

    To ask the Secretary of State for Health, what steps he is taking to improve provision of IVF as a result of the meeting held by the Parliamentary Under-Secretary of State with Monitor and NHS England on 14 December 2015.

    Jane Ellison

    Following a meeting with Fertility Fairness in December 2015, officials from the Department and NHS England are considering options for addressing variation in the prices that clinical commissioning groups are currently paying for in vitro fertilisation treatment.

  • Derek Twigg – 2016 Parliamentary Question to the Department of Health

    Derek Twigg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Derek Twigg on 2016-04-19.

    To ask the Secretary of State for Health, what plans he has to merge clinical commissioning groups during the course of the current Parliament.

    George Freeman

    There are no plans to merge clinical commissioning groups.

  • Derek Twigg – 2016 Parliamentary Question to the Department of Health

    Derek Twigg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Derek Twigg on 2016-04-19.

    To ask the Secretary of State for Health, what recent assessment he has made of the effect of the provision of urgent care centres on levels of attendance at A&E departments.

    Jane Ellison

    The location and structure of urgent and emergency care services is a matter for local commissioners, taking account of guidance issued by NHS England. This guidance includes Safer, faster better: good practice in delivering urgent and emergency care, which was published in August 2015, to support frontline providers and commissioners in re-designing urgent and emergency care services.

    The guidance states that urgent care centres co-located with emergency departments provide an opportunity to stream patients with less serious illnesses and injuries to a service that is resourced to meet their needs, while reducing crowding in emergency departments.

  • Derek Twigg – 2016 Parliamentary Question to the Department of Health

    Derek Twigg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Derek Twigg on 2016-04-19.

    To ask the Secretary of State for Health, how many people undertake quality assurance in the NHS outside of clinical commissioning groups.

    Ben Gummer

    We do not hold information centrally on the number of people working in the National Health Service who have a quality assurance role.

    However, the fundamental standards set out the standards against which care should not fall and all providers are expected to have systems and processes in place to assure themselves that they are assessing, monitoring and improving the quality and safety of their services.

    The Care Quality Commission (CQC) is responsible for the inspection and regulation of quality of all healthcare providers and its findings are published together with a performance rating. Where a provider’s performance falls below the fundamental standards the CQC has specific powers to take appropriate action.

  • Derek Twigg – 2016 Parliamentary Question to the Department of Health

    Derek Twigg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Derek Twigg on 2016-04-19.

    To ask the Secretary of State for Health, how much was spent from the public purse on the maintenance of NHS buildings in each year since 2010.

    George Freeman

    The information is not available in the format requested. Such information as is available is in the following table.

    Data is collected annually in the Estates Return Information Collection from the National Health Service for maintenance service costs (prior to 2013-14 the data collected was “total building and engineering maintenance costs”). The data for 2010 onwards is provided for the NHS below:

    £ million

    2010-11

    768.46

    2011-12

    751.40

    2012-13

    753.64

    2013-14

    756.06

    2014-15

    749.82

    The data is provided as received from the NHS and has not been amended centrally.

  • Ben Bradshaw – 2016 Parliamentary Question to the Department of Health

    Ben Bradshaw – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Ben Bradshaw on 2016-04-19.

    To ask the Secretary of State for Health, pursuant to the Answer of 23 March 2016 to Question 31117, whether there has been any lasting duration of the HPV reduction that Public Health England have associated with the bivalent vaccine.

    Jane Ellison

    The findings of Kavanagh and others, 2014, and of Mesher and others, 2016, are consistent with the reductions in human papillomavirus (HPV) 16/18 that were expected in the assessments that informed the Department’s policies. Neither of these papers report findings about genital warts incidence, both report no decrease in HPV types 6 and 11; this is also consistent with expectations in assessments that informed the Department’s policies.

    The answer of 23 March 2016 stated, ‘data reported to Public Health England (PHE) from genitourinary medicine (GUM) clinics shows a reduction in rates of genital warts diagnoses at GUM clinics between 2009 and 2014.’ This analysis has been updated with data for 2013 and 2014. The reductions reported were in patients aged 15 years and older. As the introduction of the quadrivalent vaccine was in 2012, to 12 year olds, no impact on genital warts in 15+ year olds within this time period was expected due to this introduction. Use of the quadrivalent vaccine within this age group prior to its introduction in the national immunisation programme was assessed as a possible but highly unlikely cause of the reductions seen.

    The latest data from PHE showing reductions in genital warts diagnoses in GUM clinics amongst ages offered the bivalent vaccine are data for 2014: the future duration of any protection from genital warts associated with the bivalent vaccine has not been (and cannot be) inferred.

  • Ben Bradshaw – 2016 Parliamentary Question to the Department of Health

    Ben Bradshaw – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Ben Bradshaw on 2016-04-19.

    To ask the Secretary of State for Health, pursuant to the Answer of 23 March 2016 to Question 31117, what assessment he has made of the implications for his Department’s policies of the 2016 paper by Mesher and others, Reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study; and whether such findings have been taken into account when assessing the differential impact of the bivalent and quadrivalent HPV vaccines on genital wart incidence.

    Jane Ellison

    The findings of Kavanagh and others, 2014, and of Mesher and others, 2016, are consistent with the reductions in human papillomavirus (HPV) 16/18 that were expected in the assessments that informed the Department’s policies. Neither of these papers report findings about genital warts incidence, both report no decrease in HPV types 6 and 11; this is also consistent with expectations in assessments that informed the Department’s policies.

    The answer of 23 March 2016 stated, ‘data reported to Public Health England (PHE) from genitourinary medicine (GUM) clinics shows a reduction in rates of genital warts diagnoses at GUM clinics between 2009 and 2014.’ This analysis has been updated with data for 2013 and 2014. The reductions reported were in patients aged 15 years and older. As the introduction of the quadrivalent vaccine was in 2012, to 12 year olds, no impact on genital warts in 15+ year olds within this time period was expected due to this introduction. Use of the quadrivalent vaccine within this age group prior to its introduction in the national immunisation programme was assessed as a possible but highly unlikely cause of the reductions seen.

    The latest data from PHE showing reductions in genital warts diagnoses in GUM clinics amongst ages offered the bivalent vaccine are data for 2014: the future duration of any protection from genital warts associated with the bivalent vaccine has not been (and cannot be) inferred.